Launched in October 2011, the Parallel Review program enabled the FDA and CMS to review products simultaneously, as the FDA’s device review time and CMS’ review to determine if it will to pay for a device are traditionally separate processes. Allowing for concurrent review by the two agencies will ideally shorten the overall review timeline and help new devices integrate into the market more quickly.
The extended, tentative end date for the Parallel Review program is Dec. 18, 2015.
More Articles on the FDA:
FDA Names GS1 First Accredited Issuing Agency for UDIs
FDA Updates Medical Device Recalls Database
4 Latest FDA Approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
